New combination therapy for blood cancers that haven't responded to previous treatment

Plain-English translation of NCT06859008 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing whether combined with —two new medications that work together to fight blood cancer—can help people whose cancers have come back or stopped responding to earlier treatments. The study is specifically designed to include and help people from racial and ethnic communities who have historically had fewer opportunities to participate in clinical research and access new treatments.

Many people with certain blood cancers eventually develop resistance to standard treatments, and doctors need new options to help them. This trial also aims to address unfair gaps in who gets to try cutting-edge therapies by actively recruiting people from underrepresented communities.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with a relapsed or refractory B-cell lymphoma or chronic lymphocytic leukemia that has either come back after treatment or stopped responding to it
you identify as Black or African American, Hispanic or Latino, American Indian or Native Alaskan, Pacific Islander or Native Hawaiian, or another underrepresented racial or ethnic group
you have active disease that requires treatment and meet specific criteria for your cancer type (such as having already tried at least one or two prior treatments, depending on your diagnosis)
you have measurable disease that doctors can track on imaging or physical examination

You likely don't qualify if…

you are unable or unwilling to take oral medications daily
you have severe organ damage or other serious health conditions that would make the treatment too risky
you are pregnant, breastfeeding, or unwilling to use effective birth control during the study
you have active infections or certain other cancers at the same time

What participation looks like

You will take as a daily pill for the first two months, then add the second medication, , also as a daily pill starting in month three. Treatment continues in 28-day cycles for up to 28 months (about 2 years) unless your cancer progresses or side effects become unmanageable. Throughout the study, you'll have regular blood tests, urine tests, and imaging scans (CT or MRI) to monitor how well the treatment is working, and you may also have biopsies or bone marrow samples taken at certain timepoints.

AI-generated summary from trial data · Aug 8, 2026 · Not medical advice

New combination therapy for blood cancers that haven't responded to previous treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)